ES498337A0 - Un procedimiento para la preparacion de 5-halo-pirimidin-2- onas - Google Patents

Un procedimiento para la preparacion de 5-halo-pirimidin-2- onas

Info

Publication number
ES498337A0
ES498337A0 ES498337A ES498337A ES498337A0 ES 498337 A0 ES498337 A0 ES 498337A0 ES 498337 A ES498337 A ES 498337A ES 498337 A ES498337 A ES 498337A ES 498337 A0 ES498337 A0 ES 498337A0
Authority
ES
Spain
Prior art keywords
ring
groups
heterocyclic
saturated
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES498337A
Other languages
English (en)
Other versions
ES8205399A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nyegaard and Co AS
Original Assignee
Nyegaard and Co AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nyegaard and Co AS filed Critical Nyegaard and Co AS
Publication of ES8205399A1 publication Critical patent/ES8205399A1/es
Publication of ES498337A0 publication Critical patent/ES498337A0/es
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28Halogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ES498337A 1980-01-07 1981-01-05 Un procedimiento para la preparacion de 5-halo-pirimidin-2- onas Granted ES498337A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8000381 1980-01-07

Publications (2)

Publication Number Publication Date
ES8205399A1 ES8205399A1 (es) 1982-06-01
ES498337A0 true ES498337A0 (es) 1982-06-01

Family

ID=10510470

Family Applications (2)

Application Number Title Priority Date Filing Date
ES498337A Granted ES498337A0 (es) 1980-01-07 1981-01-05 Un procedimiento para la preparacion de 5-halo-pirimidin-2- onas
ES509219A Granted ES509219A0 (es) 1980-01-07 1982-02-01 "un procedimiento para la preparacion de 5-halopirimidin-2-onas".

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES509219A Granted ES509219A0 (es) 1980-01-07 1982-02-01 "un procedimiento para la preparacion de 5-halopirimidin-2-onas".

Country Status (13)

Country Link
US (1) US4399140A (es)
EP (1) EP0032131B1 (es)
JP (1) JPS56150087A (es)
AT (1) ATE4715T1 (es)
AU (1) AU543939B2 (es)
CA (1) CA1168239A (es)
DE (1) DE3160886D1 (es)
DK (1) DK149892B (es)
ES (2) ES498337A0 (es)
IE (1) IE50765B1 (es)
NO (1) NO810024L (es)
NZ (1) NZ195947A (es)
ZA (1) ZA8164B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ197715A (en) * 1980-07-15 1984-12-14 Glaxo Group Ltd Substituted pyrimin-2-ones and pharmaceutical compositions
NZ197714A (en) * 1980-07-15 1984-11-09 Glaxo Group Ltd Substituted pyrimidin-2-ones and pharmaceutical compositions
US4596870A (en) * 1981-01-09 1986-06-24 Nyegaard & Co. A.S. Substituted pyrimidin-2-ones and the salts thereof
NO161440C (no) * 1982-02-24 1989-08-16 Nyegaard & Co As Analogifremgangsmaate for fremstilling av fysiologisk aktive pyrimidin-2-oner.
SU1235864A1 (ru) * 1983-03-11 1986-06-07 Отделение ордена Ленина института химической физики АН СССР Нитроксильные производные 5-фторурацила,обладающие противоопухолевой активностью
CN103130732A (zh) * 2011-11-22 2013-06-05 上海博康精细化工有限公司 3,5-二甲基-4-氯甲基异噁唑的制备方法
SI3164394T1 (sl) 2014-07-03 2020-08-31 Board Of Regents, The University Of Texas System GLS1 inhibitorji za zdravljenje bolezni
US20160002204A1 (en) * 2014-07-03 2016-01-07 Board Of Regents, The University Of Texas System Gls1 inhibitors for treating disease
ES2794868T3 (es) 2015-06-30 2020-11-19 Univ Texas Inhibidores de GLS1 para el tratamiento de enfermedades
KR20180095677A (ko) 2015-12-22 2018-08-27 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 (r)-1-(4-(6-(2-(4-(3,3-디플루오로시클로부톡시)-6-메틸피리딘-2-일)아세트아미도)피리다진-3-일)-2-플루오로부틸)-n-메틸-1h-1,2,3-트리아졸-4-카르복사미드의 염 형태 및 다형체
CN111225903A (zh) 2017-10-18 2020-06-02 德州大学系统董事会 谷氨酰胺酶抑制剂疗法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833586A (en) * 1971-03-25 1974-09-03 Morton Norwich Products Inc 1-(substituted benzyl)-2-(1h)pyrimidones and 1-(substituted benzyl)tetrahydro-2-(1h)pyrimidones
GB1561290A (en) * 1975-10-16 1980-02-20 Nyegaard & Co As Pyrimid - 2 - ones
US4003900A (en) * 1976-03-11 1977-01-18 Morton-Norwich Products, Inc. 1-Benzyl-5-chloro-2-(1H)-pyrimidone
US4052399A (en) * 1976-09-13 1977-10-04 Morton-Norwich Products, Inc. 1-[2-(Hexahydro-1H-azepino)ethyl]-2(1H)pyrimidone dihydrochloride
US4052400A (en) * 1976-10-29 1977-10-04 Morton-Norwich Products, Inc. Hypertensive 1-substituted 2(1h)-pyrimidones

Also Published As

Publication number Publication date
US4399140A (en) 1983-08-16
EP0032131B1 (en) 1983-09-21
IE50765B1 (en) 1986-07-09
ES8205399A1 (es) 1982-06-01
AU543939B2 (en) 1985-05-09
ZA8164B (en) 1982-03-31
IE810013L (en) 1981-07-07
NO810024L (no) 1981-07-08
CA1168239A (en) 1984-05-29
EP0032131A1 (en) 1981-07-15
ES8304946A1 (es) 1983-03-16
AU6601681A (en) 1981-07-16
NZ195947A (en) 1983-09-02
ATE4715T1 (de) 1983-10-15
JPS56150087A (en) 1981-11-20
DK149892B (da) 1986-10-20
DE3160886D1 (en) 1983-10-27
ES509219A0 (es) 1983-03-16
DK3281A (da) 1981-07-08

Similar Documents

Publication Publication Date Title
ES8101067A1 (es) Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
ES473074A1 (es) Un procedimiento para la preparacion de derivados de tieno- tiacina
DE122009000040I1 (de) Naphthalin-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.
ES498337A0 (es) Un procedimiento para la preparacion de 5-halo-pirimidin-2- onas
MX9203597A (es) Nuevos derivados de la pristinamicina iib y composiciones farmaceuticas que los contienen.
DK199885A (da) Amidinohydrazoner af tetralin-, chromon-, thiochromon- og tetrahydroquinolin-derivater, fremgangsmaader til deres fremstilling samt deresanvendelse i laegemidler
ES513177A0 (es) "un procedimiento para la preparacion de pirimidin-2-onas sustituidas".
MX7122E (es) Procedimiento para la preparacion de derivados de tiometilpiridina
DK661088D0 (da) N-(23-vinblastinoyl)derivater af 1-aminomethylphosphonsyre, fremgangsmaade til deres fremstilling og farmaceutiske midelr indeholdende dem
ES8202003A1 (es) Un procedimiento para la preparacion de derivados de ergoli-na
ES471895A1 (es) Procedimiento para preparar derivados de benzamidina
ES503985A0 (es) Un procedimiento para la preparacion de pirimidin-2-onas sustituidas

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19871118